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Introduction: Adjuvant chemotherapy in non–small cell lung
cancer (NSCLC) improves survival but is associated with sig-
niﬁcant toxicity. The Randomized Phase II Trial on Reﬁnement
of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin
and Pemetrexed versus Cisplatin and Vinorelbine (TREAT
study) was designed to test the hypothesis that a protocol with
reduced toxicity might improve feasibility of postoperative de-
livery of adjuvant chemotherapy drugs to patients with NSCLC,
thereby improving compliance and, potentially, survival.
Methods: Two adjuvant regimens were evaluated for
feasibility in 132 patients with NSCLC: the standardJournal of Thoracic Oncology Vol. 11 No. 1: 85-93
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mg/m2 on day 1 and day 8 and vinorelbine 25 mg/m2
on days 1, 8, 15, and 22 every 4 weeks) and a regimen
consisting of cisplatin and pemetrexed (CPx) (cisplatin 75
mg/m2 and pemetrexed 500 mg/m2 on day 1 every 3
weeks). The primary end-point analysis showing that CPx is
safe and feasible with dose delivery superior to that of CVb
has already been published. Here we report the 3-year
follow-up results of the secondary efﬁcacy end points—
overall, relapse-free, distant metastasis–free, and local
relapse–free survival—also with regard to histologic
diagnosis.
Results: After a median of 39 months, no signiﬁcant dif-
ferences in any of the outcome parameters between CVb
and CPx were observed. Also, histologic diagnosis and tu-
mor size in stage IB did not inﬂuence survival in the CPx-
treated patients. Yet, Cox regression analyses showed that
overall survival at 3 years was signiﬁcantly correlated with
feasibility and the occurrence of dose-limiting toxicity.
Conclusions: Although adjuvant chemotherapy with CPx is
safe and characterized by less toxicity and better dose de-
livery than CVb, overall survival was not inﬂuenced by
treatment arm in the context of this phase II trial.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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More than half of patients with non–small cell lung
cancer (NSCLC) experience recurrence after resection.1,2
The goal of postoperative adjuvant chemotherapy (ACT)
is to reduce the risk for disease recurrence by elimi-
nating residual disease that may persist after surgical
resection, thereby increasing overall survival (OS).3
Indeed, evidence from phase III studies and several
meta-analyses demonstrates that adjuvant cisplatin-
based chemotherapy (primarily cisplatin and vinor-
elbine [CVb]) confers a clear beneﬁt in terms of OS in
patients with early-stage, R0-resected NSCLC.4–14 These
results are consistent with ﬁndings in a real-life setting
from a large, retrospective population-based study that
was conducted between 2001 and 2008 and monitored
14,306 veterans with stages IB to IIIA NSCLC. In that
study, signiﬁcantly improved OS was associated with
increased use of an adjuvant platinum doublet in pa-
tients with resected NSCLC.3
ACT is the current standard of care and CVb is themost
reported chemotherapy combination option.14 However,
cisplatin-based protocols, particularly CVb, are limited by
grade 3 or 4 hematologic toxicity, mainly neutropenia,which can occur in up to 85% of patients, and febrile
neutropenia,which canoccur in up to 9%, thus resulting in
incomplete treatment delivery, therapy delay, dose re-
ductions, or even therapy-related deaths.5,7,8,15
The Randomized Phase II Trial on Reﬁnement of
Early-Stage NSCLC Adjuvant Chemotherapy with
Cisplatin and Pemetrexed versus Cisplatin and Vinor-
elbine (the TREAT study) was designed to test the hy-
pothesis that a protocol with reduced toxicity might
improve the feasibility of ACT drug delivery, compliance,
and (potentially) survival.16 Trials in patients with
advanced NSCLC and mesothelioma using a combination
of cisplatin and pemetrexed (CPx) have shown that CPx
is characterized by promising efﬁcacy and a favorable
safety proﬁle coupled with convenient once-every-3-
weeks administration.17–20 CPx was therefore chosen
for comparison with CVb from the standpoints of side
effects and dose delivery in the adjuvant setting.21
Clinical feasibility was the primary end point; it was
deﬁned as (1) no death due to cancer, toxicity, or co-
morbidity; (2) no nonacceptance by the patient leading
to premature withdrawal; and (3) no dose-limiting
toxicity (DLT), which in turn was deﬁned as grade 4
neutropenia lasting longer than 7 days, febrile grade 3 or
4 neutropenia, grade 4 thrombocytopenia lasting longer
than 7 days or any grade with bleeding, or grade 3 or 4
nonhematologic toxicity (except nausea, vomiting, and
hair loss).21
The primary and secondary end points, which were
analyzed after approximately a mean follow-up of 4
months, were reported previously.21 For the primary
end point, CPx was demonstrated to be safe and feasible.
The feasibility rate of the CPx regimen was 95.5% versus
75.4% for CVb (p < 0.001). The secondary end points
included dose delivery, which differed signiﬁcantly be-
tween treatment arms: 74.6% for CPx versus 20% for
CVb (p < 0.0001), and toxicity, which was apparent in
signiﬁcantly fewer grade 3 or 4 hematologic events in
the CPx group (10.5% versus 76.5% in the CVb group; p
< 0.0001) and a similar incidence of nonhematologic
grade 3 or 4 toxicity (33% versus 31% in the CPx and
CVb groups, respectively). Time to treatment failure
delivery was 3.6 months in the CVb group, whereas
failure of treatment delivery was not reached in the CPx
group (p < 0.001).21
Potential limitations of these results are the predic-
tive information that has emerged since initiation of the
trial (questioning the use of pemetrexed with a histologic
diagnosis of squamous cell carcinoma) and the stage
information (questioning the beneﬁt of ACT in patients
with smaller stage IB tumors22). After achievement of
the primary end point, we now report the longer-term
results of the TREAT study and key secondary out-
comes after a 3-year follow-up period.
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The full details of the TREAT trial’s design, treatment
plan, end points, eligibility criteria, toxicity management,
and follow-up modalities were reported previously.16,21
The trial was approved by the ethics committees of
every center, conducted according to good clinical
practice and the Declaration of Helsinki, and registered
at clinicaltrials.gov (identiﬁer NCT00349089). Brieﬂy,
the trial was a prospective, multicenter open label, ran-
domized phase II study that included patients who had
fully recovered after complete resection of pathologically
conﬁrmed NSCLC stages IB, IIA, IIB, and T3N1 (according
to the Tumor, Node, Metastasis [TNM] staging system,
version 6).23 Eligible tumor types were squamous cell
carcinoma, adenocarcinoma (including bronchoalveolar
differentiation), and large cell and mixed cell carcinoma
without a small cell fraction.
Patients were randomly assigned to either four cycles
of CPx (cisplatin 75 mg/m2 on day 1 and pemetrexed
500 mg/m2 on day 1) with vitamin supplementation
every 3 weeks or CVb (cisplatin 50 mg/m2 on day 1 and
day 8 and vinorelbine 25 mg/m2 on days 8, 15, and 22)
every 4 weeks. Patients were stratiﬁed according to
center, nodal status (N0 versus N1), and surgical pro-
cedure (lobectomy versus pneumonectomy). Post-
operative radiotherapy was not allowed.
The key secondary end points analyzed were relapse-
free survival (RFS) and OS. RFS was deﬁned as the in-
terval between day of surgery and date of death (from
any cause) or relapse, whichever occurred ﬁrst. OS was
deﬁned as time from surgery to death from any cause.
Additional secondary end-point parameters were local
RFS and distant metastasis–free survival. Follow-up
visits occurred at 3- to 6-month intervals for 3 years
and consisted of clinical and laboratory examination,
chest radiography complemented by computed tomog-
raphy in cases of clinically or radiologically suspected
relapse, and (optionally) abdominal ultrasonography.Statistical methods
Calculation of sample size was based on the
assumption that the experimental therapy arm would be
rated as unacceptable if the actual feasibility rate (1 –
withdrawal/DLT rate) was 65% or lower but the ther-
apy would be considered a promising candidate for
further development if the true feasibility rate reached
80% or more. The calculated total sample size was 134
patients for a type I error of 5% and a power of 80%.
Times to events were estimated by the product limit
method and compared using the log-rank test. For
analysis of potential prognostic factors, univariate
and multivariate analyses were performed by using a
proportional hazard regression model. The followingpotential prognostic factors were included: treatment,
age (<65 versus 65 years), sex, performance status at
baseline, resection type, tumor stage, tumor status (pT),
size of primary tumor (<4 cm or 4 cm), nodal status
(pN), tumor grading and histologic diagnosis, “dose de-
livery,” occurrence of DLT, and feasibility. Results were
presented as adjusted hazard ratios (HRs). The chi-
square test and Cochran-Armitage test for trend in
cases of more than two categories were used to compare
categorical variables. Continuous variables were
compared by the t-test, and p values less than 0.05 were
considered signiﬁcant in two-sided tests. No adjustment
of the error probability for multiple testing was per-
formed. SAS Release 9.2 software (SAS Institute Inc.,
Cary, NC) was used in the analysis.
Results
Patient characteristics
As described before, 132 patients were randomized,
with 67 patients treated in the CPx arm and 65 patients in
the CVb arm. The mean follow-up time was 34.1 months
(range 1.2–58.3) in the overall group, with 33.9 months
for those in the CPx group and 34.3 months for those in
the CVb group. The patients’ baseline characteristics were
evenly distributed with respect to age, sex, smoking sta-
tus, performance status, tumor stage, histologic diagnosis,
and surgical procedures21 (Table 1). Notably, 38% of
patients had stage IB disease (CPx arm 37%, CVb arm
38%) with a tumor diameter less than 4 cm in 14% (CPx
arm 16%, CVb arm 12%) and 24% had a tumor diameter
larger than 4 cm (CPx arm 21%, CVb arm 26%). Squa-
mous cell carcinoma was present in 43% of all patients
with 45% in the CPx arm and 42% in the CVb arm.
Relapses and RFS
Tumor relapse occurred in 31% of all patients: in
36% of patients receiving CPx versus 26% of patients
receiving CVb, respectively. RFS did not differ signiﬁ-
cantly (p ¼ 0.813) with medians not reached, and very
similar 3-year RFS rates (Fig. 1). In a multivariate Cox
regression analysis (Supplemental Table 1), RFS was not
signiﬁcantly inﬂuenced by chemotherapy type (HR ¼
0.831, 95% conﬁdence interval [CI]: 0.317–2.177, p ¼
0.707), but occurrence of DLT and feasibility signiﬁ-
cantly inﬂuenced RFS (p ¼ 0.024 each).
More patients in the CPx group than in the CVb group
experienced local relapses (18% versus 5%), with most
being mediastinal lymph node metastases in the CPx
group, whereas the rates of distant relapse in both
groups were similar (20.9% versus 18.5%). Brain me-
tastases occurred more frequently in the CVb arm (75%
of distant metastases) than in the CPx treatment arm
(21% of distant metastases). Local RFS and distant
Table 1. Patients’ baseline characteristics
Characteristics
CPx
(n ¼ 67)
CVb
(n ¼ 65)
Total
(N ¼ 132)
Age (range), y 58 (40–73) 60 (38–74) 59 (38–74)
Sex (%)
Male 72 77 74
Female 28 23 26
Stage (%)a
IB 37 38 38
<4 cm 16 12 14
4 cm 21 26 24
IIA 12 8 10
IIB 46 48 47
T3N1 5 6 5
Surgical procedures (%)
Lobectomy 84 82 83
Pneumonectomy 12 15 14
Complex resections 4 3 3
Histologic diagnosis (%)
Squamous cell carcinoma 45 42 43
Nonsquamous cell
carcinoma
55 58 57
 Adenocarcinoma  37  44  41
 Large cell carcinoma  9  9  9
 Mixed cell carcinoma  9  5  7
aAccording to the TNM staging system, version 6.
CPx, patients who received chemotherapy with cisplatin and
pemetrexed; CVb, patients who received chemotherapy with
cisplatin and vinorelbine; TNM, tumor, node, metastasis.
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tween treatment arms (p ¼ 0.877 and p ¼ 0.813,
respectively).Deaths and OS
The rate of death did not differ signiﬁcantly between
treatment arms, with a total rate of 27% (27% for the
CPx arm versus 26% for the CVb arm). Reasons for deathFigure 1. Relapse-free survival did not differ between the cispla
the medians not reached and similar 3-year relapse-free survivwere also comparable between groups, with 17%
attributed to tumor relapse (18% in the CPx arm and
15% in the CVb arm), 5% unrelated to therapy or tumor
(5% in each arm), and 5% unknown. Also, death by
resection type did not differ between arms: 83% of the
patients received a lobectomy, with death rates of 22%
in both arms, and 14% of patients received a pneumo-
nectomy, with a death rate of 4% for the overall cohort
(5% in the CPx arm and 3% in the CVb arm).
OS did not differ between treatment arms, with the
median not reached in the CPx arm and an OS of 59
months in the CVb arm (p ¼ 0.858) (Fig. 2). In a multi-
variate Cox regression analysis (Supplemental Table 2),
OS was not signiﬁcantly inﬂuenced by treatment arm
(HR ¼ 0.594, 95% CI: 0.165–2.131, p ¼ 0.424); once
again, however, occurrence of DLT (p ¼ 0.002) and
feasibility (p ¼ 0.002) were signiﬁcant.Inﬂuence of tumor size in stage IB and histologic
diagnosis on survival parameters
Tumor size in stage IB had no signiﬁcant impact on
RFS (HR ¼ 0.405, 95% CI: 0.038–4.277) or OS (HR ¼
1.187, 95% CI: 0.063–22.473).
OS was not inﬂuenced by whether the histologic
diagnosis was squamous cell carcinoma or adenocarci-
noma (HR ¼ 1.362, 95% CI: 0.433–4.288); the results for
comparisons of squamous cell and nonsquamous cell
carcinoma were similar (HR ¼ 1.359). Also, RFS was not
inﬂuenced by histologic diagnosis: HR ¼ 1.550 (95% CI
0.632–3.802) and HR ¼ 1.721, respectively. Neither RFS
(p ¼ 0.4183) nor OS (p ¼ 0.3634) differed signiﬁcantly
in patients with squamous cell carcinoma with regard to
chemotherapy arm (Fig. 3). Similar results were ob-
tained for patients with nonsquamous cell carcinoma, in
which case neither RFS (p ¼ 0.249) nor OS (p ¼ 0.309)
differed signiﬁcantly between treatment arms (Fig. 4).tin plus pemetrexed and cisplatin plus vinorelbine arms, with
al rates of 59% and 60%, respectively (p ¼ 0.813).
Figure 2. Overall survival did not differ between the cisplatin plus pemetrexed and cisplatin plus vinorelbine arms, with the
median survival not reached in the cisplatin plus pemetrexed arm, a rate of 59% in the cisplatin plus vinorelbine arm, and
similar 3-year overall survival rates of 75% and 77%, respectively (p ¼ 0.858).
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This is the ﬁrst study to provide survival data on CPx
as ACT for NSCLC after complete tumor resection.
After a 3-year follow-up period, no signiﬁcant sur-
vival differences between the CPx and CVb arms (the
most frequently reported chemotherapy combination for
ACT) have been demonstrated. An important and, to our
knowledge, not previously reported ﬁnding emerging
from the multivariate Cox regression analysis is that
occurrence of DLT and feasibility had a signiﬁcant
impact on survival.
This ﬁnding suggests that lowered toxicity and
therefore improved feasibility and drug delivery mayFigure 3. Overall survival for squamous non–small cell lung can
cisplatin plus vinorelbine arms (p ¼ 0.363).improve OS. Although a recent Cochrane review24 re-
ported that ACT in NSCLC is generally considered
tolerable, exposure to the current “standard” regimen
leads to signiﬁcant early toxicity. The impact of the
perception of acute toxicity by patients is a topic of
discussion; however, its true incidence and consequence
are still unknown, and it may lower drug delivery to a
signiﬁcant extent.25 In this context, our ﬁnding that OS
may be related to feasibility, which included “no
nonacceptance by the patient leading to premature
withdrawal” in its deﬁnition, adds to this discussion and
may be regarded as a relevant patient-related factor fa-
voring a more feasible regimen. In addition to early sidecer did not differ between the cisplatin plus pemetrexed and
Figure 4. Overall survival for nonsquamous non–small cell lung cancer did not differ between the cisplatin plus pemetrexed
and cisplatin plus vinorelbine arms (p ¼ 0.309).
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toxicity. A recent analysis of the International Adjuvant
Lung Trial (IALT)26 reported on a higher risk of non–
cancer-related mortality after 5 years. Therefore, the
correlation of dose limiting toxicity to survival as seen in
our trial may also be related to less late toxicity; how-
ever, this correlation is still speculative, and the low
number of patients and the short-follow-up period have
to be taken into account. Moreover, even though our
previous analysis clearly demonstrated that CPx lowers
DLT and improves feasibility compared with CVb, the
current analysis of efﬁcacy end points has not revealed
survival differences. Still, lowering acute toxicity may
reduce delayed toxic treatment effects and thereby affect
long-term survival and should therefore be explored in
further trials.
An interesting ﬁnding in our results is the nonsig-
niﬁcant differences between local and distant relapses.
Although the rate of local relapses was higher in the CPx
arm, differences for distant relapse rates were absent.
This result might be interpreted as reﬂecting the effects
of the different treatment modalities. Hypothetically,
local relapses might be inﬂuenced mainly by the efﬁcacy
of surgical therapy, whereas ACT should also be targeted
toward eradicating micrometastases and thus reducing
the rate of distant metastases. Therefore, one might
argue that the nonsigniﬁcant differences seen in local
relapse may be due to imbalances in surgical therapy in
a trial of this size, which is emphasized by the high
numbers of mediastinal lymph node relapse in the CPx
arm. On the other hand, the recent analysis of theInternational Adjuvant Lung Trial speaks against this
assumption because the trial’s authors reported that ACT
also reduced the risk of local relapse.26 Thus, this ﬁnding
is still unexplained and warrants further attention in
future studies.
There are potential limitations of a phase II study and
uncertainties regarding the degree to which they might
account for the results. Interpretation of the efﬁcacy
results of our study must be placed in the context of the
limitations inherent in a phase II study not powered to
analyze survival implications, as well as the inclusion of
a high proportion of patients with either stage IB tumors
(38% total: 14% <4 cm and 24% >4 cm) or tumors with
histologic ﬁndings of squamous cell carcinoma (43%
squamous cell versus 57% nonsquamous cell). The
correlative data on smaller tumor diameter and/or his-
tologic ﬁndings of squamous cells17,22 emerged when the
trial was already more than half recruited. It was
therefore decided to not amend the protocol—which
may have jeopardized the trial—and instead continue to
leave the inclusion of patients with stage IB or histo-
logically diagnosed squamous cell carcinoma to the
discretion of the trial centers. Although there is some
evidence to suggest that these two factors may have a
negative effect on survival outcomes, the data presented
here in both cases are insufﬁcient to provide a rationale
for or against the use of ACT in such patients and must
be interpreted in the context of the small sample size, the
follow-up time of only 3 years, and other factors. Thus,
only a prospective phase III trial with a long follow-up of
at least 5 years might address these points sufﬁciently,
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to be in place is questionable.
The ﬁrst study to establish the correlation between
tumor diameter and survival advantage was the Cancer
and Leukemia Group B study B-9633.22 An unplanned
subanalysis showed that patients with tumors larger
than 4 cm had a signiﬁcant survival advantage when
treated with ACT (HR ¼ 0.69, 95% CI: 0.48–0.99, p ¼
0.043). In a similar exploratory subgroup analysis from
the JBR.10 trial, patients with tumors smaller than 4 cm
demonstrated no signiﬁcant advantage from ACT (HR ¼
1.73, 95% CI: 0.98–3.04, p ¼ 0.06), whereas the patients
with larger tumors experienced more potentially mean-
ingful therapeutic beneﬁts (HR ¼ 0.66, 95% CI: 0.39–
1.14, p ¼ 0.13).6 However, given that both of these an-
alyses were post hoc analyses, their results must inter-
preted with caution and similarly should have been
conﬁrmed in a prospective setting. Other analyses also
failed to provide conclusive results. In the Lung Adjuvant
Cisplatin Evaluation study meta-analysis, stage IB dis-
ease showed only a trend toward an OS beneﬁt (HR ¼
0.93, 95% CI: 0.78–1.10) compared with an HR of 0.83
for stages II through IIIA.7 The subgroup analysis ac-
cording to stage from the updated NSCLC meta-analysis
revealed a consistent 5-year improvement in OS for
stage IB through stage IIIA.9 A pooled exploratory anal-
ysis performed on 538 eligible patients from the JBR.10
and CALG B-9633 trials also examined the effect of
tumor size on survival beneﬁt from adjuvant platinum-
based chemotherapy. In this multivariable analysis,
tumor size emerged as being prognostic for disease-free
survival (p ¼ 0.003) but having borderline prognostic
value for OS (p ¼ 0.1). A nonsigniﬁcant trend (p ¼ 0.24)
for increasing effect of chemotherapy on OS with
advancing tumor size was also noted.27
Correlation of histologic ﬁnding of squamous cells
with outcome of adjuvant therapy has been equally
inconclusive. A differential efﬁcacy of pemetrexed ac-
cording to histologic ﬁndings was reported in a phase
III trial by Scagliotti et al. in patients with advanced
NSCLC in 2008.17 In the early-stage NSCLC trials,
however, no prospective trial or meta-analysis demon-
strated any correlation between histologic diagnosis
and outcomes. JBR.10 actually demonstrated an
advantage for a histologic ﬁnding of squamous cells,
and poor outcomes in adenocarcinoma were reported
in the Adjuvant Navelbine International Trialist Asso-
ciation trial.4,6,7,9,28,29 Similarly, tumor histology had
no signiﬁcant effect on chemotherapy outcomes in
either the Lung Adjuvant Cisplatin Evaluation study’s
vinorelbine subgroub analysis8 or in the NSCLC meta-
analysis.9
Another limitation of our study was the brevity of its
follow-up period, which was prespeciﬁed at the time ofthe trial’s setup. We selected an analysis time point of 3
years rather than the customary 5 years or longer
needed to establish OS data; hence, we can only report
at 3 years follow-up. Mauguen et al.30 recognized the
limitations of using OS as the accepted standard end
point in clinical trials of chemotherapy and radio-
therapy for lung cancer. Although the end point is
reliable and simple to measure, it takes years to
observe in the nonmetastatic NSCLC setting. Surrogate
end points that enable earlier assessment of treatment
effects would be helpful. Their analysis of patient data
from 60 randomized trials concluded that disease-free
survival is a valid surrogate end point for OS and one
that should be explored in studies of ACT in patients
with NSCLC. As for the question of whether the time
between surgery and initiation of ACT affects OS
(because it does in colon and breast cancer), the current
literature suggests this is not the case with ACT for
NSCLC. In a multivariable analysis of 1032 patients, the
interval between surgery and ACT was not associated
with survival.14
Interest in ﬁnding more feasible regimens or
schedules providing an alternative to CVb therapy
continues to be high, and many research initiatives
exist. This search is encouraged by the results of our
phase II trial, which might be interpreted as evident
that reduction or, even better, avoidance of DLT and
improvement of feasibility by applying less toxic regi-
mens might improve survival. A series of trials have
focused on this direction. Carboplatin plus paclitaxel
showed promising results in an exploratory analysis in
patients with large tumors, although no beneﬁt has
been shown in the overall result of the stage IB trial.31
Hirai et al. recently demonstrated that a split regimen of
CVb is well tolerated for patients with resected
NSCLC.32 Further results of adjuvant CPx are expected
from the International Tailored Adjuvant Chemo-
therapy trial (EudraCT#: 2008-001764-36) and the
Eastern Cooperative Oncology Group E1505
(NCT00324805) trials. Despite a lack of level 1 data
regarding the utility of CPx in an adjuvant setting, the
National Comprehensive Cancer Network guidelines
recommend it as an option for ACT for histologic
diagnosis of nonsquamous NSCLC.33 In addition to CVb
and CPx, other regimens were included in the E1505
trial, which closed to accrual in September 2013. The
regimens included cisplatin plus gemcitabine and
cisplatin plus docetaxel, which are also named as op-
tions by the National Comprehensive Cancer Network.
In interim data presented on E1505, all four options
have been selected on a fairly equal basis for patients
enrolled in the trial.34
In conclusion, we were able to demonstrate that
ACT with CPx is safe and associated with less toxicity
92 Kreuter et al Journal of Thoracic Oncology Vol. 11 No. 1than is CVb and that in this randomized phase II study,
survival is inﬂuenced not by treatment arm but rather
by DLT and feasibility. The interpretation of efﬁcacy
data in our study needs to be weighed against the
limitations of a phase II trial, and one should be
cautious in transferring these results to the clinical
routine and, in particular, to patients with squamous
carcinoma and patients with stage IB disease. It is
important that we continue to investigate the effects of
less toxic regimens because the survival beneﬁt with
current ACT is limited. Our challenge is to decrease
toxicity and improve survival by integrating the new
drugs established as being effective in metastatic dis-
ease into the adjuvant setting. The use of longer follow-
up times or surrogate survival end points would pro-
vide a signiﬁcant advance in trials of ACT and would
provide more accurate insight as to whether less toxic
regimens may have an impact on lower rates of long-
term complications such as secondary cancers. Given
the promising efﬁcacy results shown for CPx in three
trials in later-stage NSCLC tumors17 and its demon-
strated reduced toxicity proﬁle in this trial, further
study of the effects of this regimen on survival in early-
stage NSCLC seems warranted.
Supplementary Data
Note: To access the supplementary material accompa-
nying this article, visit the online version of Journal of
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